Bryce Point Capital LLC Decreases Stock Position in Roivant Sciences Ltd. $ROIV

Bryce Point Capital LLC trimmed its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 40.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,528 shares of the company’s stock after selling 30,739 shares during the quarter. Bryce Point Capital LLC’s holdings in Roivant Sciences were worth $502,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. CWM LLC boosted its stake in shares of Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after buying an additional 920 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Roivant Sciences by 94.8% during the first quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock worth $46,000 after buying an additional 2,233 shares during the period. GAMMA Investing LLC raised its holdings in Roivant Sciences by 83.0% in the first quarter. GAMMA Investing LLC now owns 6,493 shares of the company’s stock valued at $66,000 after acquiring an additional 2,945 shares in the last quarter. UMB Bank n.a. raised its holdings in Roivant Sciences by 42.0% in the second quarter. UMB Bank n.a. now owns 5,883 shares of the company’s stock valued at $66,000 after acquiring an additional 1,740 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in Roivant Sciences by 44.8% in the first quarter. PNC Financial Services Group Inc. now owns 10,248 shares of the company’s stock worth $103,000 after acquiring an additional 3,169 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Vivek Ramaswamy sold 1,195,000 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $12.50, for a total value of $14,937,500.00. Following the completion of the sale, the insider directly owned 36,089,108 shares of the company’s stock, valued at approximately $451,113,850. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Eric Venker sold 683,818 shares of Roivant Sciences stock in a transaction on Friday, September 19th. The shares were sold at an average price of $14.95, for a total transaction of $10,223,079.10. Following the completion of the transaction, the chief executive officer directly owned 1,969,767 shares in the company, valued at $29,448,016.65. The trade was a 25.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,228,958 shares of company stock worth $76,447,638 in the last 90 days. 10.80% of the stock is currently owned by company insiders.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $19.87 on Wednesday. The company has a fifty day moving average of $15.65 and a two-hundred day moving average of $12.81. The company has a market capitalization of $13.57 billion, a PE ratio of -28.39 and a beta of 1.23. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $20.08.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ROIV. Weiss Ratings upgraded shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday, October 25th. HC Wainwright increased their target price on Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, September 18th. Guggenheim lifted their price target on Roivant Sciences from $15.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Citigroup upped their price objective on Roivant Sciences from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Leerink Partners raised their target price on Roivant Sciences from $18.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $21.06.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.